Skip to main content

CUMBERLAND PHARMACEUTICALS INC

corporate_fare Company Profile

CUMBERLAND PHARMACEUTICALS INC

CPIX·NASDAQ·Life Sciences·CIK 0001087294

Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company that acquires, develops, and sells branded prescription pharmaceuticals. The company focuses on hospital acute care, gastroenterology, and oncology markets. Cumberland promotes its approved products in the United States through its hospital, field, and oncology sales divisions. It also works with international partners to register and provide its medicines to patients in other countries. Cumberland's portfolio of brands approved by the U.S. Food and Drug Administration (FDA) includes: * **Acetadote® (acetylcysteine) injection:** Used to treat acetaminophen poisoning. * **Caldolor® (ibuprofen) injection:** Used to treat pain and fever. * **Kristalose® (lactulose) oral solution:** A prescription laxative for constipation. * **Sancuso® (granisetron) transdermal:** Prevents nausea and vomiting in patients undergoing certain chemotherapy treatments. * **Vaprisol® (conivaptan) injection:** Raises serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia. * **Vibativ® (telavancin) injection:** Treats certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, and complicated skin and skin structure infections. * **Tacilia® (omeprazole, amoxicillin, and rifabutin) oral capsule:** Treats H. pylori infection. The company has also reported results from a clinical study of its ifetroban product candidate for cardiomyopathy associated with Duchenne muscular dystrophy (DMD).

CUMBERLAND PHARMACEUTICALS INC (NASDAQ:CPIX) is a publicly traded company in the Life Sciences sector. Wiseek monitors CPIX SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • Cumberland Pharma's Ifetroban Shows Significant Reduction in Cancer Metastasis Deaths in Positive Phase 2a Trial
  • Shareholders to Vote on $100M Commercial Product Sale to Apotex, Pivoting to Development-Stage Focus
  • Shareholders to Vote on $100M Sale of Commercial Products to Apotex, Pivoting to Development-Stage Pipeline
  • Cumberland Pharmaceuticals to Sell Commercial Products for $100M, Pivoting to Development-Stage Biopharma
  • Cumberland Pharmaceuticals Reports Q1 Net Loss of $3.3M Amidst Pending $100M Apotex Deal

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$44.52M
Net Income
-$2.84M
Diluted EPS
-$0.19
Op. Cash Flow
$4.93M
Free Cash Flow
$4.83M
Gross Profit
$37.85M
Operating Income
-$2.79M
Cash & Equivalents
$11.44M
Total Debt
$0
Debt / Equity
0.00×
Net Margin
-6.4%
Shares Outstanding
14.96M sh
Source: 10-K · filed 2026-03-07 · accession 0001087294-26-000020
Browse all tickers starting with C →
$5.6
52-week range · as of 2026-05-26 $1.85 – $6.26
Market cap
$83.91M
Volume
31.8K (0.2× avg)
3-mo avg 136.9K
Live data · 2026-06-12 20:07 UTC · After hours

show_chartPrice Chart

Loading chart...

feed CPIX - Latest Insights

CPIX
Jun 02, 2026, 9:05 AM EDT
Source: PR Newswire
Importance Score:
9
Price at Filing: $5.50
Real-time Price: $5.60 info
Change: +$0.100 (+2%) info
Market Cap: $83.905M info
CPIX
May 26, 2026, 6:00 AM EDT
Filing Type: DEFM14A
Importance Score:
9
Price at Filing: $5.63
Real-time Price: $5.60 info
Change: -$0.030 (-0.53%) info
Market Cap: $83.905M info
CPIX
May 15, 2026, 4:27 PM EDT
Filing Type: PREM14A
Importance Score:
9
Price at Filing: $4.95
Real-time Price: $5.60 info
Change: +$0.650 (+13%) info
Market Cap: $83.905M info
CPIX
May 08, 2026, 5:02 PM EDT
Filing Type: 10-Q
Importance Score:
10
Price at Filing: $4.68
Real-time Price: $5.60 info
Change: +$0.920 (+20%) info
Market Cap: $83.905M info
CPIX
May 05, 2026, 5:13 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $4.41
Real-time Price: $5.60 info
Change: +$1.19 (+27%) info
Market Cap: $83.905M info
CPIX
May 05, 2026, 5:07 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.26
Real-time Price: $5.60 info
Change: +$1.34 (+31%) info
Market Cap: $83.905M info
CPIX
Apr 23, 2026, 9:02 AM EDT
Filing Type: DEFA14A
Importance Score:
10
Price at Filing: $5.04
Real-time Price: $5.60 info
Change: +$0.560 (+11%) info
Market Cap: $83.905M info
CPIX
Apr 23, 2026, 9:02 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $4.45
Real-time Price: $5.60 info
Change: +$1.15 (+26%) info
Market Cap: $83.905M info
CPIX
Apr 23, 2026, 9:01 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $5.04
Real-time Price: $5.60 info
Change: +$0.560 (+11%) info
Market Cap: $83.905M info
CPIX
Mar 06, 2026, 8:54 PM EST
Filing Type: 10-K
Importance Score:
9
Price at Filing: $3.50
Real-time Price: $5.60 info
Change: +$2.10 (+60%) info
Market Cap: $83.905M info
CPIX
Mar 03, 2026, 5:10 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.64
Real-time Price: $5.60 info
Change: +$0.956 (+21%) info
Market Cap: $83.905M info
CPIX
Feb 04, 2026, 5:20 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.94
Real-time Price: $5.60 info
Change: +$1.66 (+42%) info
Market Cap: $83.905M info